1. Medtech Insight
  2. >>Business

Bono-Backed Investment Fund Props Reflexion Medical In Final Funding Round

RefleXion Medical says it has received Series C funding from The Rise Fund, an investment fund linked to philanthropists such as U2 singer Bono that aims to support companies that not only give returns on investment, but are socially and environmentally conscious as well.

RefleXion Medical, a California-based start-up that is developing what it says is the first and only biology-guided radiotherapy system (BgRT) to individually target and treat cancers says it has raised more than $100m in Series C round funding. The company said the effort was led by The Rise Fund, an investment fund managed by TPG Growth, which is co-led by a number of philanthropic investors including U2 singer Bono and billionaire Jeff Skoll.

RefleXion notes other investment partners included T. Rowe Price Associates, GT Healthcare Capital Partners, Sofinnova Partners, KCK Group and Venrock,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Deals Shaping The Medtech And Diagnostics Industries, July 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

More from Medtech Insight

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.